Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182751 · ClinicalTrials.gov registry record · Phase 2
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT03182751: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03182751 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 128 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03182751, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
Intertrochanteric hip fractures typically result in blood loss from the fracture and require surgery that can cause further blood loss. This study is being done to look at a medication called tranexamic acid which may reduce blood loss and the need for blood transfusions associated with surgery.
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid (TXA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03182751
The ClinicalTrials.gov registry entry for NCT03182751 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03182751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03182751 about?
NCT03182751 is a clinical study titled "Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement". Intertrochanteric hip fractures typically result in blood loss from the fracture and require surgery that can cause further blood loss. This study is being done to look at a medication called tranexamic acid which may reduce blood loss and the need for blood transfusions associated with surgery.
What is the current status of trial NCT03182751?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2018-04-02. Estimated completion is 2022-05-24.
What interventions are being tested in trial NCT03182751?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (TXA) (DRUG).
Who is sponsoring clinical trial NCT03182751?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.